Last Update 03 May 26

Fair value Increased 2.94%

CYRX: Bullish Coverage And New Cryogenic Platform Will Support Future Upside

Narrative Update on Cryoport

Analysts have nudged their price target on Cryoport higher to about $13.61 from roughly $13.22, citing fresh bullish coverage and updated assumptions for revenue growth, discount rate, profit margin, and future P/E as key drivers of the revised view.

Analyst Commentary

Recent bullish coverage reflects a more constructive stance on Cryoport, with analysts formalizing their view through fresh research initiations and updated valuation work.

Bullish Takeaways

Bullish analysts frame the stock as aligned with their long term revenue growth assumptions, which helps support their updated target in the mid teens and the use of a higher future P/E in their models.
The coverage implies confidence that Cryoport can execute on its business plan well enough to justify current revenue and margin assumptions, which are key inputs to discounted cash flow and earnings based valuations.
Positive commentary around the initiation signals that analysts see a clear role for Cryoport in its end markets, which they view as supportive of medium term growth and scale benefits.
By assigning a Buy rating, bullish analysts are effectively signaling that, based on their inputs for discount rate, profitability, and growth, they see room for upside relative to where the shares have recently traded.

Bearish Takeaways

The reliance on specific assumptions for discount rate, revenue growth, and profit margin highlights that the valuation is sensitive to execution, leaving limited room for missteps on costs or volumes.
Using a higher future P/E embeds expectations for improved earnings quality and scale, which may be hard to achieve if growth, pricing, or operating leverage fall short.
Analysts acknowledge that their bullish stance depends on model inputs that may not fully capture risks such as slower contract wins, project delays, or changes in customer spending patterns.
The relatively modest change in the price target, from about US$13.22 to roughly US$13.61, suggests that even supportive models still see a fairly tight balance between potential upside and execution risk.

What's in the News

Cryoport issued full year 2026 revenue guidance in a range of US$190.0m to US$194.0m, based on its current business and expectations, with management flagging that macro factors, supply chains, inflation, government actions, tariffs, FX, and other risks disclosed in SEC filings could affect actual results (company guidance).
The company launched the MVE Fusion 800 Series, a self sustaining cryogenic freezer that removes the need for a continuous liquid nitrogen supply and is designed for space constrained labs, hospitals, clinics, biorepositories, and blood and tissue banks. It offers storage for vials, blood bags, and cassettes at or below -150°C (product announcement).
The MVE Fusion technology platform, which underpins the new Fusion 800, has received the ISBER Outstanding New Product Award. This highlights industry recognition for its approach to cryogenic storage, reliability, safety, and energy efficiency (product announcement).

Valuation Changes

Fair Value: The updated fair value estimate has risen slightly to $13.61 from $13.22. This reflects a modest upward adjustment in the model.
Discount Rate: The discount rate has moved slightly higher to 8.80% from 8.72%. This indicates a small change in the risk or return assumptions used in the analysis.
Revenue Growth: The revenue growth assumption has shifted from a 3.78% decline to 9.61% growth. This marks a meaningful swing in expectations for the top line outlook.
Net Profit Margin: The net profit margin input has edged down to 15.47% from 15.69%. This points to slightly more conservative profitability assumptions.
Future P/E: The future P/E multiple has decreased to 23.93x from 24.93x. This suggests a somewhat lower valuation multiple being applied to projected earnings.

2 views

Key Takeaways

Growing demand in cell and gene therapy logistics, along with expanding partnerships, positions Cryoport for sustained revenue growth and improved operational efficiency.
Diversification into new technologies and services reduces risk, enhances competitive edge, and supports stronger long-term earnings and profit margins.
Reliance on cell and gene therapy clients, rising regulatory hurdles, infrastructure costs, and emerging competition threaten Cryoport's revenue stability, growth, and long-term margins.

Catalysts

About Cryoport

Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.What are the underlying business or industry changes driving this perspective?

Accelerating adoption and commercialization of cell and gene therapies, evidenced by record-high 728 clinical trials supported (about 70% of the industry's trials) and 18 commercial therapies, is expected to fuel sustained, long-term demand for specialized cold chain logistics, directly supporting ongoing revenue growth and recurring commercial contracts.
Strategic partnership with DHL significantly expands Cryoport's global reach and infrastructure, enhancing integration with pharma supply chains, improving scalability, and creating opportunities for larger contract wins-supporting both top-line growth and improved operational efficiency (which benefits net margins over time).
Investments in new proprietary technologies and launches-such as the next-generation MVE shippers and the IntegriCell cryopreservation service-expand Cryoport's differentiation and service portfolio, strengthening competitive positioning, supporting premium pricing, and providing a path to higher gross margins as these services scale.
Expansion of recurring BioStorage/BioServices revenue (+28% YoY) and increased animal health sales diversify revenue streams beyond cell and gene therapies, reducing concentration risk and underpinning long-term earnings resilience.
Proven ability to deliver operating leverage-with gross margin reaching 47% (and a stated goal of 55%+) and pathway to positive adjusted EBITDA-positions Cryoport to significantly expand EBITDA and net margins as revenue from new and existing services continues to scale.

Cryoport Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cryoport's revenue will grow by 9.6% annually over the next 3 years.
Analysts are not forecasting that Cryoport will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Cryoport's profit margin will increase from -23.8% to the average US Life Sciences industry of 15.5% in 3 years.
If Cryoport's profit margin were to converge on the industry average, you could expect earnings to reach $35.9 million (and earnings per share of $0.73) by about May 2029, up from -$42.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.9x on those 2029 earnings, up from -12.4x today. This future PE is lower than the current PE for the US Life Sciences industry at 36.4x.
Analysts expect the number of shares outstanding to decline by 0.56% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Cryoport's near-term revenue growth remains highly dependent on the successful commercialization and sustained patient volumes of cell and gene therapy clients; negative regulatory opinions or reduced therapy forecasts (as seen with Sarepta and five clients receiving negative FDA/MAA opinions) expose the company to concentration risk and potential volatility in future revenues.
Ongoing global economic and geopolitical uncertainties, as well as administrative/governmental policy disruptions, are already impacting customer capital spending and may continue to restrict the pace of biopharma R&D, especially in key regions like APAC and China-constraining long-term revenue growth and creating margin pressure.
Cryoport's expansion efforts require continued investments in new infrastructure and initiatives (e.g., IntegriCell service buildout, facilities in Paris, Belgium, California), which could compress gross and EBITDA margins in the absence of proportionate demand and operating leverage, negatively affecting long-term earnings.
The industry is facing the risk of increased regulatory scrutiny, tighter requirements for clinical trials, and evolving international shipping rules; such changes could drive up compliance and operational costs for Cryoport, erode net margins, and potentially delay or reduce customer activity.
Despite presently favorable competitive dynamics, there remains the threat of new entrants, price competition from logistics giants or in-house solutions by large pharma, and technological advances in biopreservation that may reduce the demand for specialized cryogenic logistics-potentially resulting in market share loss and declining future revenues.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $13.61 for Cryoport based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $16.0, and the most bearish reporting a price target of just $9.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $232.0 million, earnings will come to $35.9 million, and it would be trading on a PE ratio of 23.9x, assuming you use a discount rate of 8.8%.
Given the current share price of $10.35, the analyst price target of $13.61 is 24.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cryoport?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cold Chain Expansion Will Support Cell And Gene Therapies